 Home > Medical News > Medicines Company News > After 40 years of development, can the target P53 really not be a drug alone?

After 40 years of development, can the target P53 really not be a drug alone?

 Last Update: 2021-07-27
 Source: Internet
 Author: User

Tags

mdt drug

b2m gene

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Summary & Discussion

In summary, it is roughly the general characteristics of the P53 target and its drug development
.
The mechanism is still unclear and the function is too complicated.
It can be said that P53 is a single target and it is difficult to make a drug.
We often call it a "tumor suppressor gene", but in the final analysis, how to suppress cancer is still not at present.
Clear
.
Is cell cycle arrest&apoptosis&senescence&metabolism vital to P53's anti-cancer effect? Does P53 have universality to inhibit various tumor cells? The answers to these key questions can not only help us further understand the basic biological characteristics of P53, but also further guide the molecular design of effective targeted therapies
.
At present, immunotherapy has begun to penetrate into the drug development of this target, and there may be a license period in the future, but it still does not seem to be the key to solve the problem
.
However, the reason why the popularity of P53 has continued is naturally due to its special appearance characteristics, and once breakthroughs are made in this type of target, which currently seems to be unpreparable, it is believed that it will be another hot event in the industry, and This will be accompanied by a concentrated output of a large number of products
.

Reference source:

1.
Pharmacology and Therapeutics, 2020.
doi.
org/10.
1016/j.
pharmthera.
2020.
107720

2.
Biochemical Pharmacology, 2021.
doi.
org/10.
1016/j.
bcp.
2021.
114407

3.
European Journal of Medicinal Chemistry, 2019.
doi.
org/10.
1016/j.
ejmech.
2019.
05.
018

4.
Reviews on Cancer, 2021.
doi.
org/10.
1016/j.
bbcan.
2021.
188556

5.
Current Opinion in Structural Biology, 2021.
doi.
org/10.
1016/j.
sbi.
2020.
11.
005

6.
Progress in Biophysics and Molecular Biology, 2015.
doi.
org/10.
1016/j.
pbiomolbio.
2014.
12.
002

7.
European Journal of Medicinal Chemistry, 2018.
DOI: 10.
1016/j.
ejmech.
2018.
08.
099

8.
The pictures in the article are from the above-mentioned literature.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.